Literature DB >> 28529374

Unmodified electroconvulsive therapy: Concerns about reporting in a retrospective study.

Chittaranjan Andrade1, Samir Kumar Praharaj2, Nachiketa Desai3, Devavrat Harshe4, Sagar Karia5.   

Abstract

Entities:  

Year:  2017        PMID: 28529374      PMCID: PMC5419000          DOI: 10.4103/psychiatry.IndianJPsychiatry_62_17

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


× No keyword cloud information.
Sir, Ray[1] described a chart review of unmodified electroconvulsive therapy (ECT) in the Central Institute of Psychiatry, Ranchi, India, during 1990–1995. We are concerned about the casual and offhand manner in which the paper was written and the data presented. Ray[1] states that there is a lack of recent study on unmodified ECT other than a few surveys on the pattern of ECT practice based on respondent reports. This is absolutely incorrect. There is one large retrospective study[2] and two prospective studies.[34] All these studies were conducted in India and two,[23] in fact, were published in the Indian Journal of Psychiatry. None of these three landmark publications are referenced by Ray.[1] Ray[1] also does not cite and reference the position statement and guideline on unmodified ECT, jointly issued by the Indian Psychiatric Society, the Indian Association of Private Psychiatry, and the Indian Association of Biological Psychiatry,[5] which was also published in the Indian Journal of Psychiatry. This position statement and guideline[5] is the most comprehensive and authoritative document on the subject published to date, providing clarity on subjects that Ray[1] deems to be obscure. Ray[1] provides a poor description of the clinical features of the sample, no information about the ECT stimulation details, and no data and statistical analysis to support a large number of claims and conclusions, such as that there was a significant positive correlation between subconvulsive stimuli and age, total number of ECT sessions, and depression, and that there was no relationship between subconvulsive stimulation and post-ECT confusion. In the paper,[1] Table 1 refers to cognitive decline with no explanation of how this was defined and assessed; this shortcoming characterizes other constructs referred to in the paper, as well. The paper states that there were no chart notes documenting the occurrence of post-ECT headache, a well-known adverse effect of unmodified ECT;[5] how accurate, then, could the rest of the information in the charts be? Finally, there are no authors from the institution from which the data were obtained and no institutional approval for the conduct of the study and the use of the data. This concern must have escaped the reviewers of the manuscript during their blinded review.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  The safety and efficacy of benzodiazepine-modified treatments as a special form of unmodified ECT.

Authors:  Nilesh Shah; Sarika Mahadeshwar; Savita Bhakta; Mahesh Bhirud; Praveen Fernandes; Chittaranjan Andrade
Journal:  J ECT       Date:  2010-03       Impact factor: 3.635

2.  Musculoskeletal morbidity with unmodified ect may be less than earlier believed.

Authors:  C Andrade; K Rele; R Sutharshan; S Nilesh
Journal:  Indian J Psychiatry       Date:  2000-04       Impact factor: 1.759

3.  Physical morbidity with unmodified ect - a decade of experience.

Authors:  P Tharyan; P J Saju; S Datta; J K John; K Kuruvilla
Journal:  Indian J Psychiatry       Date:  1993-10       Impact factor: 1.759

4.  Position statement and guidelines on unmodified electroconvulsive therapy.

Authors:  Chittaranjan Andrade; N Shah; P Tharyan; M S Reddy; M Thirunavukarasu; R A Kallivayalil; R Nagpal; N K Bohra; A Sharma; E Mohandas
Journal:  Indian J Psychiatry       Date:  2012-04       Impact factor: 1.759

5.  How bad was unmodified electroconvulsive therapy! A retrospective study.

Authors:  Anindya Kumar Ray
Journal:  Indian J Psychiatry       Date:  2016 Apr-Jun       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.